Plain-English translation of NCT06287749 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This French research study is testing whether a special blood test can help predict which pancreatic cancer patients are most likely to have their cancer return after surgery and chemotherapy. The blood test looks for tiny pieces of cancer DNA that leak into the bloodstream. By detecting this cancer DNA at specific points during treatment, doctors hope to identify high-risk patients earlier and potentially adjust their care plan.
Even after surgery and chemotherapy, most pancreatic cancer patients experience cancer recurrence within two years. There is currently no standard way to detect early warning signs that cancer may be coming back. This study aims to develop a reliable blood test that could alert doctors sooner when the cancer is returning, potentially giving patients more treatment options.
You likely qualify if…
You likely don't qualify if…
As a participant, you would have blood drawn at several scheduled time points before surgery, after surgery, and after completing chemotherapy treatment. These blood samples will be analyzed to detect cancer DNA and track whether it is present or disappearing over time. The study will follow your health status for up to three years to see whether the blood test results can predict who experiences cancer recurrence.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
France